Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NL-OMON59818Phase 2Recruiting
Phase 2, single-arm trial of baclofen in gamma-hydroxybutyrate use disorder (GHBUD), sponsored by Radboud University Medical Center. Primary endpoint: Pharmaceutical GHB dosage at end of titration phase. Started Jun 2025; status: recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NL-OMON59818.